An in vivo platform for rapid high-throughput antitubercular drug discovery.
about
Next-generation antimicrobials: from chemical biology to first-in-class drugsFit for consumption: zebrafish as a model for tuberculosisPhylogenetic analysis of vitamin B12-related metabolism in Mycobacterium tuberculosis.Zebrafish small molecule screens: Taking the phenotypic plungeProtection and pathology in TB: learning from the zebrafish modelEstablishment and validation of whole-cell based fluorescence assays to identify anti-mycobacterial compounds using the Acanthamoeba castellanii-Mycobacterium marinum host-pathogen systemIdentification of benzopyrone as a common structural feature in compounds with anti-inflammatory activity in a zebrafish phenotypic screenEvaluation of the pathogenesis and treatment of Mycobacterium marinum infection in zebrafish.Organ-targeted high-throughput in vivo biologics screen identifies materials for RNA delivery.Utilization of zebrafish for intravital study of eukaryotic pathogen-host interactions.In vivo assessment of drug efficacy against Mycobacterium abscessus using the embryonic zebrafish test system.Testing tuberculosis drug efficacy in a zebrafish high-throughput translational medicine screenAdequate Th2-type response associates with restricted bacterial growth in latent mycobacterial infection of zebrafishNeutrophils in host defense: new insights from zebrafish.Mycobacterium marinum Degrades Both Triacylglycerols and Phospholipids from Its Dictyostelium Host to Synthesise Its Own Triacylglycerols and Generate Lipid InclusionsAdventures within the speckled band: heterogeneity, angiogenesis, and balanced inflammation in the tuberculous granuloma.Mycobacterium abscessus cording prevents phagocytosis and promotes abscess formation.Mycobacteria manipulate macrophage recruitment through coordinated use of membrane lipidsThe Diverse Cellular and Animal Models to Decipher the Physiopathological Traits of Mycobacterium abscessus Infection.Immunity and Immunopathology in the Tuberculous GranulomaUnconventional screening approaches for antibiotic discovery.Cell and small animal models for phenotypic drug discovery.A fluorescence-based reporter for monitoring expression of mycobacterial cytochrome bd in response to antibacterials and during infection.A Macrophage Response to Mycobacterium leprae Phenolic Glycolipid Initiates Nerve Damage in Leprosy.β-CA-specific inhibitor dithiocarbamate Fc14-584B: a novel antimycobacterial agent with potential to treat drug-resistant tuberculosis.Mycobacterial ESX-1 secretion system mediates host cell lysis through bacterium contact-dependent gross membrane disruptions.Screening in larval zebrafish reveals tissue-specific distribution of fifteen fluorescent compounds.Phenolic Glycolipid Facilitates Mycobacterial Escape from Microbicidal Tissue-Resident Macrophages.TNF dually mediates resistance and susceptibility to mycobacteria via mitochondrial reactive oxygen species.Cardiotoxicity evaluation of anthracyclines in zebrafish (Danio rerio).Hit Generation in TB Drug Discovery: From Genome to Granuloma.Development and Characterization of an Endotoxemia Model in Zebra Fish.
P2860
Q26799749-F69DB0A3-ACE6-4000-AE91-C9C88384DCD7Q26827390-5E84F6E1-5419-4366-BCBF-B2FD8C85C713Q27687284-2BAA6122-8BA9-4E23-A6F3-13FD2B379CF9Q28073655-34347B13-0B46-4B51-92DE-E49FC23214FEQ28266814-3F4DAA73-3C3E-4C84-B50C-56C6E454440DQ28539402-DAD28987-954D-4081-BE47-72B4CAD55E08Q28828964-36BA0188-A869-47EB-97AB-A18713FB1FD7Q30571358-AEE76A5C-71AA-442C-8025-0DB4345788DEQ30624869-4118F3F7-CC70-41A1-AC48-40CB74C89050Q33638779-7EC26B78-DCAB-4FA3-A1E0-5785ED1C5A74Q33798263-AB23D8E7-8AC4-48BA-84CE-56E835A4D85AQ35106008-AFE05AD7-7862-4179-BA39-8AA5E2D63AE0Q35195622-7C32342A-0484-4B75-AEBC-35D286E7B0F9Q36057930-9C18E8E0-73A4-4575-865E-DA59A2164FDAQ36254134-A0958819-7661-4F8C-B918-D8FA59875755Q36439790-C8BCCAC5-176B-40F4-8964-6A3EC0F6C65AQ37640941-FD93AD20-CF23-4CC9-872A-1D9AA9EACDCAQ37653944-E32EC042-C819-4E3F-946D-52E53A8610F5Q37735996-E58A953A-184D-475F-888C-295B4763BCF0Q38265850-EE65EB8D-CA5D-4602-BC65-110697112331Q38534653-7761BFEF-0E65-42CF-827F-2F1636021083Q39442815-66B6A3E1-99D2-4DCD-BE11-00BE3BA3E506Q40063754-EE07BCB0-29F8-4A1D-BCA7-9381E0D1DAA3Q40079614-5ABB2313-AD54-4553-A307-B7F123D89D2CQ40166814-5C664A0D-F93B-4AB3-BE25-96D4BBD58BDAQ40359526-F7EA8ED1-A393-4269-8691-508C073B1ECAQ41664825-AE07C544-EDD5-40CD-A3B1-D887A164CC7AQ41665668-5B257759-D6C5-4C53-9864-17C567F24E57Q41816750-84CF58E6-367D-4E9A-A60B-6712C1A696BEQ45775622-B8FCB5ED-FDBE-4840-8545-04089753F6CBQ47702665-7566BD20-6621-4AA0-9D3D-CA91F01A0BDDQ54236611-DDDD37D2-93CB-4256-902B-084D4F61F595
P2860
An in vivo platform for rapid high-throughput antitubercular drug discovery.
description
2012 nî lūn-bûn
@nan
2012年の論文
@ja
2012年論文
@yue
2012年論文
@zh-hant
2012年論文
@zh-hk
2012年論文
@zh-mo
2012年論文
@zh-tw
2012年论文
@wuu
2012年论文
@zh
2012年论文
@zh-cn
name
An in vivo platform for rapid high-throughput antitubercular drug discovery.
@en
type
label
An in vivo platform for rapid high-throughput antitubercular drug discovery.
@en
prefLabel
An in vivo platform for rapid high-throughput antitubercular drug discovery.
@en
P2093
P2860
P1433
P1476
An in vivo platform for rapid high-throughput antitubercular drug discovery.
@en
P2093
Christine L Cosma
Kevin Takaki
Mark A Troll
P2860
P304
P356
10.1016/J.CELREP.2012.06.008
P577
2012-07-20T00:00:00Z